Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10145372 | 0.87 | ALDH1A1 (0.41) | HCRTR1HCRTR2GPR119ALOX5APFEN1 | |
| SCHEMBL7869396 | 0.83 | CNR1 (0.38) | SYKHCRTR1HCRTR2GPR119 | |
| SCHEMBL10144799 | 0.83 | GPR119 (0.36) | SYKGPR119LIPEALOX5APFEN1 | |
| SCHEMBL10145425 | 0.82 | GPR119 (0.36) | GPR119LIPEALOX5APFEN1 | |
| SCHEMBL10144962 | 0.81 | HCRTR1 (0.39) | HCRTR1GPR119LIPEALOX5APFEN1 | |
| SCHEMBL27158490 | 0.80 | GPR119 (0.51) | SYKGPR119LIPEALOX5APFEN1 | |
| SCHEMBL10144964 | 0.79 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL10145376 | 0.78 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL10145584 | 0.77 | GRM5 (0.36) | ALOX5APFEN1USP30 | |
| SCHEMBL10145340 | 0.77 | HCRTR1 (0.52) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | SYK 4413/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.